The MAP strategy prevented no-reflow in 100% of STEMI patients undergoing percutaneous coronary intervention, achieving TIMI flow grade 2 or 3 with no deaths at 9 months.
Observational (n=71)
No
Does the 'MAP strategy' prevent no-reflow in patients with STEMI undergoing PCI?
The 'MAP strategy' combining thrombus aspiration, tirofiban, and prolonged balloon/stent inflation was safe and associated with no incidence of no-reflow in STEMI patients undergoing PCI.
'No-reflow' phenomenon is a common occurrence in percutaneous coronary intervention (PCI). A three-component 'MAP strategy' was designed to prevent no-reflow by addressing both intralesional and intraluminal thrombus in patients with ST-segment elevation myocardial infarction (STEMI). In this analysis, we observed Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 or 2 in all patients, with no incidence of no-reflow. Myocardial blush grade (MBG) 3 or 2 was observed in most (87.32%) patients. Left ventricular ejection fraction (LVEF) was improved, without any incidence of death up to 9-month follow-up. All patients safely tolerated the strategy-driven prolonged, 35-s inflation of the balloon/stent.
Potdar et al. (Tue,) conducted a observational in ST-segment elevation myocardial infarction (STEMI) (n=71). MAP strategy (Maximum aspiration, adjunctive GP IIb/IIIa inhibitor, prolonged balloon/stent inflation) was evaluated on Incidence of no-reflow (TIMI flow grade 0 or 1). The MAP strategy prevented no-reflow in 100% of STEMI patients undergoing percutaneous coronary intervention, achieving TIMI flow grade 2 or 3 with no deaths at 9 months.